SF3B1 and glioblastoma: Remarkably, GDSC-dataset analysis also unveiled a potential implication of SF3B1 dysregulation in different oncogenic pathways (e.g., mTOR-PI3K/cell cycle/DNA replication, etc.)to confer drug resistance in GBM, which further encourages the use of an SF3B1 specific-inhibitor in GBM.